Photo of Manya Magnus

Manya Magnus, PhD, MPH

Title:
Associate Professor and Associate Chair, Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington University
Office:
Floor 5
Address: 950 New Hampshire Avenue NW
Washington, District Of Columbia
20052
Phone: 202-994-3024
Email:
manyadm@gwu.edu
Website:

Current HIV/AIDS Research Activities:

  • George Washington University HIV Prevention Trials Network Clinical Research Site: Site Leader
  • Co-Director, DC CFAR Clinical and Population Sciences Core

Current studies:

  • HPTN 085/HVTN 704, HVTN 704/HPTN 085, A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men
  • HPTN 077, A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
  • Structural barriers to HIV prevention service utilization among Black MSM (NIH/NIMH 1 R21 MH097586-02): Principal Investigator
  • Use of telemedicine to overcome barriers to care among transgender women of color (NIH/NIMHD 1R21MD008624-02): Principal Investigator
  • National HIV Behavioral Surveillance study (part of the Department of Epidemiology and Biostatistics/HAA Public Health/Academic Partnership)-CDC/DC DOH: Co-Investigator
  • Mucosal Immune Responses in the Reproductive Tract of Post-Menopausal Women: Impact of sexual violence and HIV status (5P30AI087714) (PI: Ghosh/Greenberg) Co-Investigator/Mentor
  • Advancing Pre-exposure Prophylaxis (PrEP) Delivery among Black MSM in the District of Columbia (5P30AI087714) (PI: Siegel/Greenberg) Co-Investigator/Mentor

Studies coming soon:

  • HPTN 083, A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men

Closed studies:

  • HPTN 069, A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC+TDF), or Tenofovir disoproxil fumarate + Emtricitabine (TDF+FTC) For Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission in At-Risk Men Who Have Sex with Men and in At-Risk Women
  • HPTN 073, Pre Exposure Prophylaxis (PrEP) Initiation and Adherence among Black Men who have Sex with Men (BMSM) in Three US Cities
  • HPTN 061, Feasibility of a community-level, multi-component intervention for Black MSM in preparation for a Phase IIB community-level randomized trial to test the efficacy of the intervention in reducing HIV incidence among Black MSM
  • HPTN 064, The Women's HIV SeroIncidence Study (ISIS)

Current HIV/AIDS Educational Activities

  • Course Director, Epidemiology of HIV/AIDS, GWU SPH, Department of Epidemiology and Biostatistics
  • Course Director, Advanced Epidemiologic Methods (Spring), GWU SPH, Department of Epidemiology and Biostatistics
  • Co-Director, MPH Program in Epidemiology